

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) May 19, 2026

KORU Medical Systems, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

0-12305
(Commission
File Number)

13-3044880
(IRS Employer
Identification No.)

100 Corporate Drive, Mahwah, NJ
(Address of principal executive offices)

07430
(Zip Code)

Registrant's telephone number, including area code (845) 469-2042

not applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of each class</u>	<u>Trading symbol(s)</u>	<u>Name of each exchange on which registered</u>
common stock, \$0.01 par value	KRMD	The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.07. Submission of Matters to a Vote of Security Holders.

Set forth below are the voting results from the 2026 Annual Meeting of Shareholders held on May 19, 2026:

Total shares voted: 36,678,784

Proposal 1: Election of Directors

The nominees for director set forth under "Nominees" below were elected to the Company's board of directors.

Nominees	Number of Shares			
	For	Against	Abstain	Broker Non-Vote
R. John Fletcher	25,202,422	647,041	8,671	10,820,650
Robert A. Cascella	25,635,760	213,703	8,671	10,820,650
Donna French	25,801,738	41,675	14,721	10,820,650
Joseph M. Manko, Jr.	25,794,709	54,754	8,671	10,820,650
Shahriar (Shar) Matin	25,800,075	41,322	16,737	10,820,650
Linda Tharby	25,446,988	402,677	8,469	10,820,650
Edward Wholihan	25,804,371	44,791	8,972	10,820,650

Proposal 2: Approval of an amendment to the 2024 Omnibus Equity Incentive Plan to increase the available number of shares.

The Company's shareholders approved the amendment to the 2024 Omnibus Equity Incentive Plan to increase the available number of shares.

	For	Against	Abstain	Broker Non-Vote
Number of Shares	25,018,973	826,145	13,016	10,820,650

Proposal 3: Advisory approval of the compensation of the Company's executive officers.

The Company's shareholders, on an advisory basis, approved the compensation of the Company's executive officers.

	For	Against	Abstain	Broker Non-Vote
Number of Shares	25,723,379	91,649	43,106	10,820,650

Proposal 4: Advisory approval of the frequency of future votes on executive compensation.

The Company's shareholders, on an advisory basis, approved the frequency of future votes on executive compensation to be every one year.

	1 Year	2 Years	3 Years	Abstain	Broker Non-Vote
Number of Shares	24,865,692	61,741	916,055	14,646	10,820,650

Proposal 5: Ratification of the appointment of independent registered accountants for the 2026 fiscal year.

The Company's shareholders ratified the appointment of Cherry Bekaert LLP as the company's independent registered public accountants for the 2026 fiscal year.

	For	Against	Abstain
Number of Shares	36,500,510	19,629	158,645

- 2 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

KORU Medical Systems, Inc.
(Registrant)

Date: May 19, 2026

By: /s/ Linda Tharby
Linda Tharby
Chief Executive Officer

- 3 -
